Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 10, 2016, Pages 1133-1142

  Himebauch, Adam S ^a,b   Kilbaugh, Todd J ^a   Zuppa, Athena F ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

ECMO; pediatric; pharmacodynamics; pharmacokinetics

Indexed keywords

AMIODARONE; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; CASPOFUNGIN; CEFOTAXIME; CLAVULANIC ACID; DEXMEDETOMIDINE; DIURETIC AGENT; FLUCONAZOLE; GENTAMICIN; INOTROPIC AGENT; ISOFLURANE; OPIATE; OSELTAMIVIR; PARACETAMOL; PHENOBARBITAL; PROPOFOL; RANITIDINE; RIBAVIRIN; SEDATIVE AGENT; SILDENAFIL; THEOPHYLLINE; TICARCILLIN; VANCOMYCIN; VASODILATOR AGENT; VORICONAZOLE; DRUG;

DRUG DISPOSITION; DRUG DISTRIBUTION; EXTRACORPOREAL OXYGENATION; HEART FAILURE; HUMAN; NONHUMAN; RESPIRATORY FAILURE; REVIEW; ANIMAL; BIOLOGICAL MODEL; CHILD; CRITICAL ILLNESS; DOSE RESPONSE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; METABOLISM; PERSONALIZED MEDICINE; PHARMACOKINETICS; PROCEDURES;

ANIMALS; CHILD; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PRECISION MEDICINE;

EID: 84987789007     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2016.1201066     Document Type: Review

References (118)

1. A.F.Zuppa, J.S.Barrett Pharmacokinetics and pharmacodynamics in the critically ill child. Pediatr Clin North Am. 2008;55(3):735–755.
2. J.M.Varghese, J.A.Roberts, J.L.Lipman. Pharmacokinetics and pharmacodynamics in critically ill patients. Curr Opin Anaesthesiol. 2010;23(4):472–478.
3. J.A.Roberts, M.H.Abdul-Aziz, J.Lipman, et al. Individualised antibiotic dosing for patients who are critically ill:challenges and potential solutions. Lancet Inf Dis. 2014;14(6):498–509.• Good review changes in pharmacokinetics associated with critical care and how this may affect antibiotic dosing and efficacy.
4. R.D.Jaquiss, R.A.Bronciki. An overview of mechanical circulatory support in children. Pediatr Crit Care Med. 2013;14(5 Suppl 1):S3–6.
5. A.Maslach-Hubbard, S.L.Bratton. Extracorporeal membrane oxygenation for pediatric respiratory failure:history, development, and current status. World J Crit Care Med. 20132;4:29–39.
6. D.HayesJr, J.D.Tobias, J.Kukreja, et al. Extracorporeal life support for acute respiratory distress syndromes. Ann Thorac Med. 2013;8(3):133–141.
7. R.H.Bartlett, L.Gattinoni. Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiol. 2010;76(7):534–540.
8. O.Dagan, J.Klein, C.Gruenwald, et al. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit. 1993;15(4):263–3.
9. G.Koren, P.Crean, J.Klein, et al. Sequestration of fentanyl by the cardiopulmonary bypass (CPBP). Eur J Clin Pharmacol. 1984;27:51–56.
10. A.van Saet, S.N.De Wildt, C.A.Knibbe, et al. The effect of adult and pediatric cardiopulmonary bypass on pharmacokinetic and pharmacodynamic parameters. Curr Clin Pharamcol. 2013;8(4):297–318.
11. E.D.Wildschut, A.van Saet, P.Pokorna, et al. The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children. Pediatr Clin N Am. 2012;59:1183–1204.
12. M.L.Buck. Pharmacokinetic changes during extracorporeal membrane oxygenation:implications for drug therapy of neonates. Clin Pharmacokinet. 2003;42(5):403–417.
13. K.Shekar, J.F.Fraser, M.T.Smith, et al. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27:741.e9–18.
14. E.D.Wildschut, M.J.Ahsman, R.J.Houmes, et al. Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO). Curr Drug Metab. 2012;13(6):767–777.
15. D.A.Rosen, K.R.Rosen, D.L.Silvasi. In vitro variability in fentanyl absorption by different membrane oxygenators. J Cardiothorac Anesth. 1990;4(3):332–335.
16. H.Mulla, G.Lawson, C.Von Anrep, et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion. 2000;15:21–26.
17. V.Bhatt-Meht, G.Annich. Sedative clearance during extracorporeal membrane oxygenation. Perfusion. 2005;20:309–315.
18. N.M.Mehta, D.R.Halwick, B.L.Dodson, et al. Potential drug sequestration during extracorporeal membrane oxygenation:results from an ex vivo experiment. Intensive Care Med. 2007;33(6):1018–1024.
19. E.D.Wildschut, M.J.Ahsman, K.Allegaert, et al. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010;36:2109–2116.• Comprehensive in vitro study investigating circuit sequestration of various drugs with different types and components of ECMO circuits.
20. T.J.Preston, A.B.Hodge, J.B.Riley, et al. In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. J Extra Corpor Technol. 2007;39:234–237.
21. T.J.Preston, T.M.Ratliff, D.Gomez, et al. Modified surface coatings and their effect on drug absorption within the extracorporeal life support circuit. J Extra Corpor Technol. 2010;42(3):199–202.
22. K.Shekar, J.A.Roberts, C.I.Mcdonald, et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16(5):R194.
23. D.Wagner, D.Pasko, K.Phillips, et al. In vitro clearance of dexmedetomidine in extracorporeal membrane oxygenation. Perfusion. 2013;28(1):40–46.
24. F.Lemaitre, N.Hasni, P.Leprince, et al. Propofol, midazolam, vancomycin, and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit Care. 2015;19:40.
25. A.A.Harthan, K.W.Buckley, M.L.Heger, et al. Medication adsorption into contemporary membrane oxygenator units. J Pediatr Pharmacol Ther. 2014;19(4):288–295.
26. A.Gillogly, C.Kilbourn, J.Waldvogel, et al. In vitro clearance of intravenous acetaminophen in extracorporeal membrane oxygenation. Perfusion. 2013;28(2):141–145.
27. K.Shekar, J.A.Roberts, C.I.Mcdonald, et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit:results from an ex vivo study. Crit Care. 2015;19:164.• In vitro demonstration of how highly protein-bound drugs are sequestered in ECMO circuit.
28. K.Shekar, J.A.Roberts, A.G.Barnett, et al. Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models. Crit Care. 2015;19:437.
29. K.M.Watt, D.K.BenjaminJr, I.M.Cheifetz, et al. Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J. 2012;31(10):1042–1047.• Interesting application of a clinical problem that was addressed with a comprehensive pharmacokinetic study with associated pharmacodynamic targets.
30. G.J.Peek, R.K.Firmin. The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. Asaio J. 1999;45(4):250–263.
31. N.J.Vet, M.De Hoog, Tibboel, et al. The effect of inflammation on drug metabolism:a focus on pediatrics. Drug Discov Today. 2011;16(9–10):250–263.
32. G.L.Kearns, S.M.Abdel-Rahman, S.W.Alander, et al. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–1167.
33. R.H.Bartlett. Extracorporeal life support for cardiopulmonary failure. Cur Probl Surg. 1990;27(10):621–705.
34. J.A.Carcillo, L.Doughty, D.Kofos, et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med. 2003;29(6):980–984.
35. T.Alkan-Bozkaya, A.Akçevin, H.Türkoğlu, et al. Impact of pulsatile perfusion on clinical outcomes of neonates and infants with complex pathologies undergoing cardiopulmonary bypass procedures. Artif Organs. 2013;37(1):82–86.
36. J.J.Talor, A.Undar. Pediatric cardiopulmonary bypass:does perfusion mode matter? World J Pediatr Congenit Heart Surg. 2011;2(2):296–300.
37. M.P.O’Neil, J.C.Fleming, A.Badhwar, et al. Pulsatile versus nonpulsatile flow during cardiopulmonary bypass:microcirculatory and systemic effects. Ann Thorac Surg. 2012;94(6):2046–2053.
38. B.J.Roy, J.D.Cornish, R.H.Clark. Venovenous extracorporeal membrane oxygenation affects renal function. Pediatrics. 1995;95(4):573–578.
39. V.Bhatt-Mehta, C.E.Johnson, R.E.Schumacher. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1992;12(1):28–32.
40. K.Shekar, J.A.Roberts, S.Ghassabian, et al. Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation:cause for concern? J Antimicrob Chemother. 2013;68(3):726–727.
41. N.J.Vet, E.Ista, S.N.De Wildt, et al. Optimal sedation in pediatric intensive care patients:a systematic review. Intensive Care Med. 2013;39:1524–1534.
42. M.A.Q.Curley, D.Wypij, S.Watson, et al. Protocolized sedation vs usual care in pediatric patients mechanically ventilated for acute respiratory failure:a randomized control trial. Jama. 2015;313(4):379–389.
43. C.W.M.Verlaat, G.P.Heesen, N.J.Vet, et al. Randomized controlled trial of daily interruption of sedatives in critically ill children. Pediatr Anaesth. 2013;24(2):151–156.
44. B.B.DeBerry, J.E.Lynch, J.M.Chernin, et al. A survey for pain and sedation medications in pediatric patients during extracorporeal membrane oxygenation. Perfusion. 2005;20(3):139–143.
45. L.Fonsmark, Y.H.Rasmussen, P.Carl. Occurrence of withdrawal in critically ill sedated children. Crit Care Med. 1999;27(1):196–199.
46. C.Ducharme, F.A.Carnevale, M.S.Clermont, et al. A prospective study of adverse reactions to the weaning of opioids and benzodiazepines among critically ill children. Intensive Crit Care Nurs. 2005;21(3):179–186.
47. E.Ista, M.van Dijk, C.Gamel, et al. Withdrawal symptoms in critically ill children after long-term administration of sedatives and/or analgesics:a first evaluation. Crit Care Med. 2008;36(8):2427–2432.
48. A.W.Loepke. Developmental neurotoxicity of sedatives and anesthetics:a concern for neonatal and pediatric critical care medicine? Pediatr Crit Care Med. 2010;11(2):217–226.
49. J.H.Arnold, R.D.Truog, J.M.Scavone, et al. Changes in pharmacodynamic response to fentanyl in neonates during continuous infusion. J Pediatr. 1991;119(4):639–643.
50. M.P.Leuschen, L.D.Willett, E.Hoie, et al. Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 1993;105(5):885–891.
51. O.Dagan, J.Klein, D.Bohn, et al. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med. 1994;22(7):1099–1101.
52. K.Shekar, J.A.Roberts, D.V.Mullany, et al. Increased sedation requirements in patients receiving extracorporeal membrane oxygenation for respiratory and cardiorespiratory failure. Anaesth Intensive Care. 2012;40:648–655.
53. C.L.Hodgson, E.Fan. A step up for extracorporeal membrane oxygenation:active rehabilitation. Respir Care. 2013;58(8):1388–1389.
54. J.H.Arnold, R.D.Truog, E.J.Orav, et al. Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation. Anesthesiology. 1990;73:1136–1140.
55. J.M.Geiduschek, A.M.Lynn, S.L.Bratton, et al. Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. Crit Care Med. 1997;25(2):360–364.
56. J.W.Peters, B.J.Anderson, S.H.Simons, et al. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med. 2005;31(2):257–263.
57. J.W.Peters, B.J.Anderson, S.H.Simons, et al. Morphine metabolite pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet. 2006;45(7):705–714.
58. L.S.Franck, J.Vilardi, D.Durand, et al. Opioid withdrawal in neonates after continuous infusions of morphine or fentanyl during extracorporeal membrane oxygenation. Am J Crit Care. 1998;7(5):364–369.
59. M.J.Ahsman, M.Hanekamp, E.D.Wildschut, et al. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet. 2010;49(6):407–419.
60. H.Mulla, P.McCormack, G.Lawson, et al. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology. 2003 Aug;99(2):275–282.
61. E.Hammaren, P.H.Rosenberg, M.Hynynen. Coating of extracorporeal circuit with heparin does not prevent sequestration of propofol in vitro. Br J Anaesth. 1999;82(1):38–40.
62. D.A.Diedrich, D.R.Brown. Propofol infusion syndrome in the ICU. J Intensive Care Med. 2011;26(2):59–72.
63. C.Wiesenack, G.Wiesner, C.Keyl, et al. In vivo uptake and elimination of isoflurane by different membrane oxygenators during cardiopulmonary bypass. Anesthesiology. 2002 Jul;97(1):133–138.
64. G.W.Kaczala, S.C.Paulus, N.Al-Dajani, et al. Bloodstream infections in pediatric ECLS:usefulness of daily blood culture monitoring and predictive value of biological markers. The British Columbia experience. Pediatr Surg In. 2009;25(2):169–173.
65. M.J.Bizzarro, S.A.Conrad, D.A.Kaufman, et al. Extracorporeal life support organization task force on infections, extracorporeal membrane oxygenation. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med. 2011;12(3):277–281.
66. W.A.Craig. Pharmacokinetic/pharmacodynamic parameters:rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10.
67. E.B.Hoie, S.A.Swigart, M.P.Leuschen, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm. 1990;9(9):711–715.
68. R.D.Amaker, J.T.DiPiro, J.Bhatia. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1996;40(5):1139–1142.
69. M.L.Buck. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1998;18(5):1082–1086.
70. H.Mulla, S.Pooboni. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2005;60(3):265–275.
71. W.M.Southgate, J.T.DiPiro, A.F.Robertson. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1989;33(6):817–819.
72. P.Cohen, L.Collart, C.G.Prober, et al. Gentamicin pharmacokinetics in neonates undergoing extracorporeal membrane oxygenation. Pediatr Infect Dis J. 1990;9(8):562–566.
73. P.J.Munzenberger, N.Massoud. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans. 1991;37(1):16–18.
74. W.F.Dodge, R.W.Jelliffe, J.B.Zwischenberger, et al. Population pharmacokinetic models:effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit. 1994;16(6):552–559.
75. M.J.Ahsman, E.D.Wildschut, D.Tibboel, et al. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2010;54(5):1734–1741.
76. C.A.Lindsay, R.Bawdon, R.Quigley. Clearance of ticarcillin-clavulonic acid by continuous venovenous hemofiltration in three critically ill children, two with and one without concomitant extracorporeal membrane oxygenation. Pharmacotherapy. 1996;16(3):458–462.
77. E.D.Wildschut, M.De Hoog, M.J.Ahsman, et al. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One. 2010;5(6):e10938.
78. R.F.Eyler, K.C.Klein, B.A.Mueller. The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis. J Pediatr Pharmacol Ther. 2012;17(2):173–176.
79. C.Aebi, C.L.Headrick, G.H.McCracken, et al. Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation:pharmacokinetics and clearance by hemofiltration. J Pediatr. 1997;130(4):612–615.
80. R.J.Brüggemann, T.Antonius, A.V.Heijst, et al. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. Ther Drug Monit. 2008;30(6):643–646.
81. I.Spriet, P.Annaert, P.Meersseman, et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2009;63(4):767–770.
82. S.Ruiz, E.Papy, D.Da Silva, et al. Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation. Intensive Care Med. 2009;35(1):183–184.
83. B.Koch, E.D.Wildschut, A.L.De Goede, et al. Insufficient serum caspofungin levels in a paediatric patient on ECMO. Med Mycol Case Rep. 2012;2:23–24.
84. M.M.van der Vorst, E.Wildschut, R.J.Houmes, et al. Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation. Crit Care. 2006;10(6):R168.
85. M.M.van der Vorst, J.den Hartigh E.Wildschut, et al. An exploratory study with an adaptive continuous intravenous furosemide regimen in neonates treated with extracorporeal membrane oxygenation. Crit Care. 2007;11(5):R111.
86. T.G.Wells, J.W.Fasules, B.J.Taylor, et al. Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. J Pediatr. 1992;121(6):974–980.
87. B.F.McBride, C.M.White, M.Campbell, et al. Nicardipine to control neonatal hypertension during extracorporeal membrane oxygen support. Ann Pharmacother. 2003;37:667–670.
88. J.D.Tobias, J.B.Pietsch, A.Lynch. Nicardipine to control mean arterial pressure during extracorporeal membrane oxygenation. Pediatr Anaesth. 1996;6:57–60.
89. T.Smith, D.A.Rosen, P.Russo, et al. Nesiritide during extracorporeal membrane oxygenation. Pediatr Anaesth. 2005;15:152–157.
90. J.G.Kendrick, J.J.Macready, N.Kissoon. Amiodarone treatment of junctional ectopic tachycardia in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother. 2006;40:1872–1875.
91. B.Robinson, E.Eshaghpour, S.Ewing, et al. Hypertrophic obstructive cardiomyopathy in an infant of a diabetic mother:support by extracorporeal membrane oxygenation and treatment with beta-adrenergic blockade and increased intravenous fluid administration. Asaio J. 1998;44:845–847.
92. M.J.Ahsman, B.C.Witjes, E.D.Wildschut, et al. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed. 2010;95(2):F109–14.
93. T.G.Wells, M.J.Heulitt, B.J.Taylor, et al. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation. J Clin Pharmacol. 1998;38(5):402–407.
94. A.Saini, P.C.Spinella. Management of anticoagulation and hemostasis for pediatric extracorporeal membrane oxygenation. Clin Lab Med. 2014;34(3):655–673.
95. G.Annich, I.Adachi. Anticoagulation for pediatric mechanical circulatory support. Pediatr Crit Care Med. 2013;14(5 Suppl 1):S37–42.
96. C.F.Stocker, S.B.Horton. Anticoagulation strategies and difficulties in neonatal and pediatric extracorporeal membrane oxygenation (ECMO). Perfusion. 2016;31(2):95–102.
97. T.P.Green, B.Isham-Schopf, R.J.Irmiter, et al. Inactivation of heparin during extracorporeal circulation in infants. Clin Pharmacol Ther. 1990;48(2):148–154.
98. E.S.Elliott, M.L.Buck. Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother. 1999;33(4):419–422.
99. H.Mulla, F.Nabi, S.Nichani, et al. Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2003;55(1):23–31.
100. G.R.Martin, L.Chauvin, B.L.Short. Effects of hydralazine on cardiac performance in infants receiving extracorporeal membrane oxygenation. J Pediatr. 1991;118:944–948.
101. D.M.Stone, D.A.Frattarelli, S.Karthikeyan, et al. Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease. Pediatr Cardiol. 2006;27(3):360–363.
102. M.L.Paden, S.A.Conrad, P.T.Rycus, et al. Extracorporeal life support organization registry report 2012. ASAIO Journal. 2013;59:202–210.
103. B.J.Anderson, A.F.Merry. Data sharing for pharmacokinetic studies. Pediatr Anaesth. 2009;19(10):1005–1010.
104. I.Ince, S.N.de Wildt, D.Tibboel, et al. Tailor-made drug treatment for children:creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today. 2009;14(5–6):316–320.
105. K.Shekar, J.A.Roberts, S.Welch, et al. ASAP ECMO:antibiotic, sedative, and analgesic pharmacokinetics during extracorporeal membrane oxygenation:a multi-centre study to optimize drug therapy during ECMO. BMC Anesthesiol. 2012;12:29.
106. M.M.Laughon, D.K.BenjaminJr, E.V.Capparelli, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol. 2011;4(5):643–652.
107. F.M.Musteata. Pharmacokinetic applications of microdevices and microsampling techniques. Bioanalysis. 2009;1(1):171–185.
108. W.Li, F.L.Tse. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr. 2010;24(1):49–65.
109. P.M.Edelbroek, J.van der Heijden, L.M.Stolk. Dried blood spot methods in therapeutic drug monitoring:methods, assays, and pitfalls. Ther Drug Monit. 2009;31(3):327–336.
110. L.Nováková, H.Vlcková. A review of current trends and advances in modern bio-analytical methods:chromatography and sample preparation. Anal Chim Acta. 2009;656(1–2):8–35.
111. J.S.Millership. Microassay of drugs and modern measurements techniques. Paediatr Anaesth. 2011;21(3):197–205.
112. B.J.Anderson. My child is unique; the pharmacokinetics are universal. Paediatr Anaesth. 2012;22(6):530–538.
113. V.Tod Jullien, G.Pons. Facilitation of drug evaluation in children by population methods and modeling. Clin Pharmacokinet. 2008;47(4):231–243.
114. C.A.Knibbe, E.H.Krekels, M.Danhof. Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol. 2011;7(1):1–8.
115. C.M.T.Sherwin, T.K.L.Kiang, M.G.Spigarelli, et al. Fundamentals of population pharmacokinetic modeling:validation methods. Clin Pharmacokinet. 2012;51(9):573–590.
116. J.S.Barrett, O.Della Casa Alberighi, S.Läer, et al. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther. 2012;92(1):40–49.
117. N.Holford, S.C.Ma, B.A.Ploeger. Clinical trial simulation:a review. Clin Pharmacol Ther. 2010;88(2):166–182.
118. J.Bělohlávek, D.Springer, M.Mlček, et al. Early vancomycin, amikacin and gentamicin concentrations in pulmonary artery and pulmonary tissue are not affected by VA ECMO (venoarterial extracorporeal membrane oxygenation) in a pig model of prolonged cardiac arrest. Pulm Pharmacol Ther. 2013 Dec;26(6):655–660.